An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.

Oula C MansourAbraham NudelmanAda RephaeliDon R PhillipsSuzanne M CuttsBenny J Evison

Published in: Cancer chemotherapy and pharmacology (2022)

The features unique to pixantrone-DNA adducts may be leveraged to enhance cancer cell kill and may be used to guide the design of pixantrone analogues that generate adducts with more favorable anticancer properties.

Keyphrases

circulating tumor
cell free
single molecule
structure activity relationship
nucleic acid
circulating tumor cells